Skip to main content
SpringerLink
Log in

Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The effects of stem cell transplantation (SCT) in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) remain controversial. We analyzed the feasibility of SCT and risk factors associated with outcomes of PTCL-NOS and AITL patients to identify the potential clinical efficacy of SCT. We retrospectively analyzed the data of PTCL-NOS (n = 83) and AITL (n = 112) patients who received autologous (n = 10 and 16, respectively) or allogeneic (n = 12 and 4, respectively) SCT, or no SCT (n = 61 and 92, respectively) between 2008 and 2018. All PTCL-NOS and AITL diagnoses were reconfirmed by an experienced hematopathologist. Median age at PTCL-NOS and AITL diagnoses in the SCT group was younger than that in the no SCT group. Significant risk factors for lower overall survival were intermediate–high and high-risk international prognostic indexes in PTCL-NOS patients (P = 0.0052), and a > 2 modified prognostic index for T-cell lymphoma (P = 0.0079) and no SCT (P = 0.028) in AITL patients. Autologous or allogeneic SCT compared with no SCT in AITL patients resulted in 3-year overall survival of 68.6% and 100% vs. 57.2% (P = 0.018). Strategies should be developed to improve selection of PTCL-NOS and AITL patients suitable for SCT and/or additional novel therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017.

    Google Scholar 

  2. Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51:25–34.

    Article  Google Scholar 

  3. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol. 2018;26:4124–30.

    Google Scholar 

  4. Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176:851–66.

    Article  CAS  Google Scholar 

  5. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176:750–8.

    Article  CAS  Google Scholar 

  6. Cheson BD. Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. Curr Opin Hematol. 2009;16:299–305.

    Article  CAS  Google Scholar 

  7. Maruyama D, Tobinai K, Ogura M, Uchida T, Hatake K, Taniwaki M, et al. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. Int J Hematol. 2017;106:655–65.

    Article  CAS  Google Scholar 

  8. Gisselbrecht C, Sibon D. New perspectives in the therapeutic approach of peripheral T-cell lymphoma. Curr Opin Oncol. 2018;30:285–91.

    Article  Google Scholar 

  9. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.

    Article  CAS  Google Scholar 

  10. d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma:NLG-T-01. J Clin Oncol. 2012;30:3093–9.

    Article  CAS  Google Scholar 

  11. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:1826–38.

    Article  Google Scholar 

  12. Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:627–52.

    Article  Google Scholar 

  13. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:218–24.

    CAS  PubMed  Google Scholar 

  14. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–9.

    Article  Google Scholar 

  15. Yin J, Wei J, Xu JH, Xiao Y, Zhang YC. Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis. Acta Haematol. 2014;131:114–25.

    Article  CAS  Google Scholar 

  16. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533–8.

    Article  CAS  Google Scholar 

  17. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19:958–63.

    Article  CAS  Google Scholar 

  18. Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016;91:672–6.

    Article  CAS  Google Scholar 

  19. Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715–23.

    Article  CAS  Google Scholar 

  20. Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. he impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018;97:1241–50.

    Article  Google Scholar 

  21. Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol. 2015;26:386–92.

    Article  CAS  Google Scholar 

  22. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27:3951–8.

    Article  Google Scholar 

  23. Wulf G, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M, et al. Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma:efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transplant. 2019;54:877–84.

    Article  CAS  Google Scholar 

  24. Gu Z, Wang L, Wang Q, Li H, Bo J, Wang S, et al. Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas. Ann Hematol. 2019;98:1237–47.

    Article  CAS  Google Scholar 

  25. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.

    Article  CAS  Google Scholar 

  26. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472–9.

    Article  CAS  Google Scholar 

  27. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402–8.

    Article  CAS  Google Scholar 

  28. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.

    Article  Google Scholar 

  29. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  Google Scholar 

  30. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010;45:311–6.

    Article  CAS  Google Scholar 

  31. Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95:1513–9.

    Article  CAS  Google Scholar 

  32. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum-report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2009;15:367–9.

    Article  Google Scholar 

  33. Yamasaki S, Chihara D, Kim SW, Kawata T, Mizuta S, Ago H, et al. Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. Int J Hematol. 2019;109:175–86.

    Article  CAS  Google Scholar 

  34. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  Google Scholar 

  35. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.

    Article  Google Scholar 

  36. Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27:719–24.

    Article  CAS  Google Scholar 

  37. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6.

    Article  CAS  Google Scholar 

  38. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008;26:2264–71.

    Article  Google Scholar 

  39. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938–47.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank the patients and clinical staff for their participation in the study. We appreciate Akishiko Numata, Goichi Yoshimoto, Yasuo Mori (Kyushu University Hospital), Takuro Kuriyama, Yayoi Matsuo, Masayasu Hayashi, and Tomonori Shimokawa (Hamanomachi Hospital) for checking the medical records. The authors also acknowledge the Clinical Research Institute, Kyushu Medical Hospital for editorial support. We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. All named authors meet the International Committee of Medical Journal Editors criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Funding

No funding or sponsorship was received for this study or publication of this article. The article processing charges were funded by the authors.

Author information

Authors and Affiliations

  1. Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-Ku, Fukuoka, 810-8563, Japan

    Satoshi Yamasaki & Hiromi Iwasaki

  2. Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan

    Shuro Yoshida, Hideho Henzan & Tetsuya Eto

  3. Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Koji Kato, Toshihiro Miyamoto & Koichi Akashi

  4. Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

    Ilseung Choi & Youko Suehiro

  5. Department of Hematology, St. Maria Hospital, Kurume, Japan

    Yutaka Imamura

  6. Department of Medicine, Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, Japan

    Kentaro Kohno & Ryosuke Ogawa

  7. Department of Hematology, Fukuoka Red Cross Hospital, Fukuoka, Japan

    Hideho Henzan & Kazuki Tanimoto

  8. Department of Pathology, Kurume University, Kurume, Japan

    Koichi Ohshima

Authors
  1. Satoshi Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuro Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilseung Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yutaka Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kentaro Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideho Henzan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuki Tanimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ryosuke Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Youko Suehiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshihiro Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tetsuya Eto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Koichi Ohshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Koichi Akashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hiromi Iwasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Fukuoka Blood and Marrow Transplantation Group

Contributions

SY designed the study, analyzed the data, and prepared the manuscript., SY, KK, IC, YI, K/K, HH., KT., RO., YS., TM, TE, KO, KA, and HI prepared and reviewed the manuscript. All authors approved the final manuscript.

Corresponding author

Correspondence to Satoshi Yamasaki.

Ethics declarations

Conflict of interest

Koji Kato: Consulting or advisory role with AbbVie, AstraZeneca, Celgene, Chugai, Eisai, Janssen, and Novartis. Honoraria from Chugai, Takeda, MSD, Kyowa-Kirin, Janssen, Celgene, Ono, Dainippon-Sumitomo, AbbVie, Novartis. Research funding from Chugai, Takeda, Kyowa-Kirin, Abbvie, Eisai, Janssen, Novartis, Mundi, AstraZeneca, Celgene, Ono, MSD, and Otsuka. The other authors declare that there are no competing financial interests regarding this article.

Ethical approval

The present study was retrospective and did not involve any experimental intervention, which was approved by the Institutional Review Board of Kyushu Medical Center.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

12185_2020_2879_MOESM1_ESM.pptx

Supplemental Figure 1. Flow chart of patients included in this analysis. Supplemental Figure 2. Kaplan-Meier estimates of OS of PTCL-NOS patients after the landmark time (A, 2 months from diagnosis; B, 4 months from diagnosis; C, 6 months from diagnosis). Supplemental Figure 3. Kaplan-Meier estimates of OS of AITL patients after the landmark time (A, 2 months from diagnosis; B, 4 months from diagnosis; C, 6 months from diagnosis).1 (PPTX 172 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamasaki, S., Yoshida, S., Kato, K. et al. Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. Int J Hematol 112, 74–83 (2020). https://doi.org/10.1007/s12185-020-02879-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02879-w

Keywords

Search

Navigation